ArticleIBRO neuroscience reports2026
Investigating the effects of chlorogenic acid on novel object recognition memory impairment, hyperlocomotion, and prefrontal BDNF expression in a sub-chronic ketamine-induced schizophrenia-like rat model.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a severe neuropsychiatric disorder characterized by positive, negative, cognitive, mood-related, and motor symptoms. Sub-chronic ketamine administration is widely used to induce schizophrenia-like behavioral and cognitive alterations in rodents. Chlorogenic acid (CGA) is an abundant dietary phenolic acid with reported anti-inflammatory, antioxidative, and neuroprotective properties. The present study examined the effects of CGA on behavioral disturbances in male and female rats exposed to sub-chronic ketamine administration, together with brain-derived neurotrophic factor (BDNF) expression in the prefrontal cortex. Ketamine was injected for 7 consecutive days (30 mg/kg, i.p.), and CGA was orally administered once (150 mg/kg) 24 h after the last ketamine injection. Ketamine increased locomotor activity in both sexes, with a greater effect in females; CGA partially reduced this effect only in males. Rearing was reduced only in ketamine-treated males, and CGA did not reverse this change. Grooming was increased in both sexes after ketamine administration, whereas CGA attenuated this effect only in females. Novel object recognition memory was impaired in both sexes after ketamine administration, and CGA partially attenuated this impairment. Immobility in the forced swim test was reduced only in ketamine-treated females, and CGA attenuated this effect. Prefrontal BDNF expression was decreased after ketamine administration in both sexes, and CGA partially attenuated this reduction. Overall, CGA showed partial and sex-dependent protective effects against selected ketamine-induced behavioral and molecular alterations. These findings should be interpreted in light of the absence of independent DMSO-only vehicle-control cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.